CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
BI 765080drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05075772
NCT05075772Phase 1Completed
CompareCT.gov

Absolute Bioavailability, Safety, Tolerability, and Pharmacodynamics Following Subcutaneous (SC) Injection of 100 mg BI 765080 Relative to Intravenous (IV) Dose in Healthy Male Subjects

Boehringer Ingelheim·interventional·Posted Oct 13, 2021·Updated Aug 13, 2024

In Brief

A Phase 1 clinical trial evaluating BI 765080 for Healthy. Completed, enrolled 28 participants across 1 site.

Detailed Summary

A study in healthy man to investigate the absolute bioavailability of 100mg BI 765080, once administered as subcutaneous (SC) injection and once administered as intravenous infusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedOct 13, 2021
Enrollment StartOct 25, 2021
Primary CompletionMar 11, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.7 years ago

Interventions

BI 765080drug

BI 765080